Cargando…

Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort

OBJECTIVES: To validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict thrombosis recurrence in APS. METHODS: Consecutive thrombotic-APS patients were included. aGAPSS, Padua and Caprini score at baseline were collected...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yuan, Huang, Can, Qi, Wanting, Zhou, Yangzhong, Zhao, Jiuliang, Wang, Qian, Tian, Xinping, Li, Mengtao, Zhao, Yan, Zeng, Xiaofeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387646/
https://www.ncbi.nlm.nih.gov/pubmed/37507205
http://dx.doi.org/10.1136/rmdopen-2023-003084
_version_ 1785081929485254656
author Zhao, Yuan
Huang, Can
Qi, Wanting
Zhou, Yangzhong
Zhao, Jiuliang
Wang, Qian
Tian, Xinping
Li, Mengtao
Zhao, Yan
Zeng, Xiaofeng
author_facet Zhao, Yuan
Huang, Can
Qi, Wanting
Zhou, Yangzhong
Zhao, Jiuliang
Wang, Qian
Tian, Xinping
Li, Mengtao
Zhao, Yan
Zeng, Xiaofeng
author_sort Zhao, Yuan
collection PubMed
description OBJECTIVES: To validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict thrombosis recurrence in APS. METHODS: Consecutive thrombotic-APS patients were included. aGAPSS, Padua and Caprini score at baseline were collected. Harrell c-index and calibration curve were used to validate the prediction models. RESULTS: 362 patients were enrolled. The mean age was 36.30±13.88 years old, and 209 (57.7%) were female. Patients were followed up for a median of 2.32 years, with 32 (8.84%) venous and 21 (5.80%) arterial thrombosis. The 1-year, 3-year and 5-year thrombosis risks were 5.0%, 14.3% and 17.9%, respectively. The Harrell c-indexes of aGAPSS, Padua and Caprini score were 0.54 (95% CI 0.44 to 0.64), 0.54 (95% CI 0.46 to 0.62), and 0.50 (95%CI 0.42 to 0.58), respectively. Padua score had the best discrimination to predict venous thrombosis (Harrell c-index=0.61, 95% CI 0.53 to 0.69). aGAPSS had the best discrimination to predict arterial thrombosis (Harrell c-index=0.61, 95% CI 0.47 to 0.75). The calibrations for predicting thrombosis within 1, 3 and 5 years of the three models were suboptimal. CONCLUSION: The performance of aGAPSS, Padua and Caprini score to predict thrombosis recurrence in APS were suboptimal. Arterial and venous thrombosis recurrence predictors were different. New prediction models are required for venous and arterial thrombosis separately.
format Online
Article
Text
id pubmed-10387646
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-103876462023-08-01 Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort Zhao, Yuan Huang, Can Qi, Wanting Zhou, Yangzhong Zhao, Jiuliang Wang, Qian Tian, Xinping Li, Mengtao Zhao, Yan Zeng, Xiaofeng RMD Open Autoimmunity OBJECTIVES: To validate the performance of the adjusted global antiphospholipid syndrome (APS) score (aGAPSS), Padua score and Caprini score to predict thrombosis recurrence in APS. METHODS: Consecutive thrombotic-APS patients were included. aGAPSS, Padua and Caprini score at baseline were collected. Harrell c-index and calibration curve were used to validate the prediction models. RESULTS: 362 patients were enrolled. The mean age was 36.30±13.88 years old, and 209 (57.7%) were female. Patients were followed up for a median of 2.32 years, with 32 (8.84%) venous and 21 (5.80%) arterial thrombosis. The 1-year, 3-year and 5-year thrombosis risks were 5.0%, 14.3% and 17.9%, respectively. The Harrell c-indexes of aGAPSS, Padua and Caprini score were 0.54 (95% CI 0.44 to 0.64), 0.54 (95% CI 0.46 to 0.62), and 0.50 (95%CI 0.42 to 0.58), respectively. Padua score had the best discrimination to predict venous thrombosis (Harrell c-index=0.61, 95% CI 0.53 to 0.69). aGAPSS had the best discrimination to predict arterial thrombosis (Harrell c-index=0.61, 95% CI 0.47 to 0.75). The calibrations for predicting thrombosis within 1, 3 and 5 years of the three models were suboptimal. CONCLUSION: The performance of aGAPSS, Padua and Caprini score to predict thrombosis recurrence in APS were suboptimal. Arterial and venous thrombosis recurrence predictors were different. New prediction models are required for venous and arterial thrombosis separately. BMJ Publishing Group 2023-07-28 /pmc/articles/PMC10387646/ /pubmed/37507205 http://dx.doi.org/10.1136/rmdopen-2023-003084 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Autoimmunity
Zhao, Yuan
Huang, Can
Qi, Wanting
Zhou, Yangzhong
Zhao, Jiuliang
Wang, Qian
Tian, Xinping
Li, Mengtao
Zhao, Yan
Zeng, Xiaofeng
Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort
title Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort
title_full Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort
title_fullStr Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort
title_full_unstemmed Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort
title_short Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort
title_sort validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort
topic Autoimmunity
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387646/
https://www.ncbi.nlm.nih.gov/pubmed/37507205
http://dx.doi.org/10.1136/rmdopen-2023-003084
work_keys_str_mv AT zhaoyuan validationofthreepredictionmodelsforthrombosisrecurrenceinantiphospholipidsyndromepatientsbasedonaprospectivecohort
AT huangcan validationofthreepredictionmodelsforthrombosisrecurrenceinantiphospholipidsyndromepatientsbasedonaprospectivecohort
AT qiwanting validationofthreepredictionmodelsforthrombosisrecurrenceinantiphospholipidsyndromepatientsbasedonaprospectivecohort
AT zhouyangzhong validationofthreepredictionmodelsforthrombosisrecurrenceinantiphospholipidsyndromepatientsbasedonaprospectivecohort
AT zhaojiuliang validationofthreepredictionmodelsforthrombosisrecurrenceinantiphospholipidsyndromepatientsbasedonaprospectivecohort
AT wangqian validationofthreepredictionmodelsforthrombosisrecurrenceinantiphospholipidsyndromepatientsbasedonaprospectivecohort
AT tianxinping validationofthreepredictionmodelsforthrombosisrecurrenceinantiphospholipidsyndromepatientsbasedonaprospectivecohort
AT limengtao validationofthreepredictionmodelsforthrombosisrecurrenceinantiphospholipidsyndromepatientsbasedonaprospectivecohort
AT zhaoyan validationofthreepredictionmodelsforthrombosisrecurrenceinantiphospholipidsyndromepatientsbasedonaprospectivecohort
AT zengxiaofeng validationofthreepredictionmodelsforthrombosisrecurrenceinantiphospholipidsyndromepatientsbasedonaprospectivecohort